Johnson & Johnson (JNJ) Shares Sold by ING Groep NV

ING Groep NV lowered its position in Johnson & Johnson (NYSE:JNJ) by 35.5% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 549,961 shares of the company’s stock after selling 303,352 shares during the quarter. Johnson & Johnson makes up about 1.3% of ING Groep NV’s portfolio, making the stock its 15th biggest position. ING Groep NV’s holdings in Johnson & Johnson were worth $66,732,000 at the end of the most recent reporting period.

Other large investors have also recently made changes to their positions in the company. Lowe Brockenbrough & Co. Inc. lifted its holdings in shares of Johnson & Johnson by 2.0% during the 2nd quarter. Lowe Brockenbrough & Co. Inc. now owns 107,921 shares of the company’s stock valued at $13,095,000 after purchasing an additional 2,076 shares during the last quarter. Merriman Wealth Management LLC lifted its holdings in shares of Johnson & Johnson by 12.1% during the 2nd quarter. Merriman Wealth Management LLC now owns 9,258 shares of the company’s stock valued at $1,123,000 after purchasing an additional 996 shares during the last quarter. Richard Bernstein Advisors LLC lifted its holdings in shares of Johnson & Johnson by 5.4% during the 2nd quarter. Richard Bernstein Advisors LLC now owns 103,670 shares of the company’s stock valued at $12,579,000 after purchasing an additional 5,356 shares during the last quarter. Sawtooth Solutions LLC lifted its holdings in shares of Johnson & Johnson by 37.5% during the 2nd quarter. Sawtooth Solutions LLC now owns 12,911 shares of the company’s stock valued at $1,567,000 after purchasing an additional 3,523 shares during the last quarter. Finally, Aviance Capital Partners LLC lifted its holdings in shares of Johnson & Johnson by 1.8% during the 2nd quarter. Aviance Capital Partners LLC now owns 23,097 shares of the company’s stock valued at $2,802,000 after purchasing an additional 419 shares during the last quarter. 66.51% of the stock is currently owned by institutional investors.

JNJ has been the subject of several analyst reports. Raymond James increased their price objective on Johnson & Johnson from $144.00 to $149.00 and gave the company an “outperform” rating in a report on Wednesday, October 17th. Credit Suisse Group increased their price objective on Johnson & Johnson from $149.00 to $152.00 and gave the company an “outperform” rating in a report on Wednesday, October 17th. Citigroup increased their price objective on Johnson & Johnson from $137.00 to $148.00 and gave the company a “neutral” rating in a report on Monday, October 22nd. Zacks Investment Research lowered Johnson & Johnson from a “buy” rating to a “hold” rating in a report on Tuesday. Finally, Wells Fargo & Co reiterated an “outperform” rating and set a $160.00 price objective (up previously from $155.00) on shares of Johnson & Johnson in a report on Wednesday, October 17th. Two analysts have rated the stock with a sell rating, seven have given a hold rating and ten have issued a buy rating to the stock. The stock has an average rating of “Hold” and a consensus target price of $143.90.

Shares of JNJ stock opened at $145.43 on Friday. The firm has a market capitalization of $391.78 billion, a P/E ratio of 19.92, a PEG ratio of 2.28 and a beta of 0.59. The company has a quick ratio of 1.40, a current ratio of 1.72 and a debt-to-equity ratio of 0.46. Johnson & Johnson has a 1 year low of $118.62 and a 1 year high of $148.99.

Johnson & Johnson (NYSE:JNJ) last issued its earnings results on Tuesday, October 16th. The company reported $2.05 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $2.03 by $0.02. The company had revenue of $20.35 billion during the quarter, compared to analyst estimates of $20.05 billion. Johnson & Johnson had a return on equity of 34.62% and a net margin of 1.89%. The firm’s quarterly revenue was up 3.6% on a year-over-year basis. During the same quarter last year, the business posted $1.90 EPS. Analysts forecast that Johnson & Johnson will post 8.16 EPS for the current fiscal year.

The company also recently announced a quarterly dividend, which will be paid on Tuesday, December 11th. Investors of record on Tuesday, November 27th will be paid a $0.90 dividend. The ex-dividend date is Monday, November 26th. This represents a $3.60 dividend on an annualized basis and a yield of 2.48%. Johnson & Johnson’s dividend payout ratio (DPR) is 49.32%.

In related news, EVP Michael E. Sneed sold 30,943 shares of the firm’s stock in a transaction on Friday, November 23rd. The stock was sold at an average price of $142.46, for a total value of $4,408,139.78. Following the completion of the transaction, the executive vice president now owns 70,817 shares in the company, valued at approximately $10,088,589.82. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, VP Peter Fasolo sold 166,695 shares of the firm’s stock in a transaction on Tuesday, December 4th. The stock was sold at an average price of $146.41, for a total value of $24,405,814.95. Following the completion of the transaction, the vice president now owns 155,540 shares of the company’s stock, valued at approximately $22,772,611.40. The disclosure for this sale can be found here. Insiders sold a total of 510,544 shares of company stock valued at $74,414,877 in the last 90 days. 0.22% of the stock is currently owned by company insiders.

ILLEGAL ACTIVITY NOTICE: This piece was first posted by American Banking News and is the sole property of of American Banking News. If you are viewing this piece on another domain, it was illegally stolen and reposted in violation of US & international copyright legislation. The original version of this piece can be accessed at https://www.americanbankingnews.com/2018/12/08/johnson-johnson-jnj-shares-sold-by-ing-groep-nv.html.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment includes products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women’s health, and wound care markets.

Read More: Hedge Funds – Risk or Reward?

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply